ProtAffin Biotechnologie AG
This article was originally published in Start Up
Executive Summary
ProtAffin Biotechnologie AG's technology is based on the interactions between pro-inflammatory proteins such as chemokines, and leucocytes and endothelial cells that drive many acute and chronic inflammatory processes such as ischemia/reperfusion injury and rheumatoid arthritis. The company's CellJammer platform uses structural bioinformatics and rational protein engineering to take a target protein agonist that naturally binds to a GAG ligand and to create an antagonist that binds with higher affinity and blocks the target protein-GAG interaction.
You may also be interested in...
Glycan Biosciences Inc.
While recent advances have revealed the chemical structures of glycosaminoglycans and their enormous biological importance, cost-effective and scalable synthesis has been a consistent barrier to commercialization. Glycan Biosciences thinks it's solved the problem with its chemistry platform, Glycolink, which uses inexpensive pharmaceutical-grade feedstocks, simplified chemistry, and employs only a few steps. The technology has yielded numerous promising NCEs, including some for respiratory disease, Glycan's primary therapeutic target.
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.